QUANTA Lite ENA Profile EIA - inova

Referencias1. Mongey AB, Hess EV. Antinuclear Antibodies and Disease Specificity. Adv Intern Med, 1991. 36:151-169.2. Moore TL et al. Extractable Nuclear Antigens. Seminars in Arthritis and Rheumatism, 1981. 10 No.2: 309-318.3. Nakamura et al. Advances in Laboratory Tests for Autoantibodies to Nuclear Antigens in SystemicRheumatic Diseases. Laboratory Medicine. 1984. 15 No.3:190-198.4. White RH, Robbins DL. Clinical Significance and Interpretation of Antinuclear Antibodies. West J Med,1987. 147: 210-213.5. Nakamura RM, Tan M. Recent Progress in the Study of Autoantibodies to Nuclear Antigens. HumanPathology. 1978. 9 No.1:85-91.6. Hardin JA et al. The Molecular Biology of Autoantibodies. Arthritis Foundation Atlanta GA. 1987. Chapter 7:32-36.7. Maddison PJ et al. Antibodies to nRNP, Sm, Ro(SSA), and La(SSB) detected by ELISA: their specificityand inter-relations in connective tissue disease sera. Clin Exp Immunol, 1985. 62: 337-345.8. Harley JB, Yamagata H, Reuchlin M. Anti-La/SSA Antibody is Present in Some Normal Sera and isCoincident with Anti-Ro/SSA Precipitins in Systemic Lupus Erythematosus. J Rheumatol, 1984. 11: 309-314.9. Reichlin M. Clinical and Immunological Significance of Antibodies to Ro and La in Systemic LupusErythematosus. Arthritis and Rheumatism, 1982. 25, No.7: 767-772.10. Mitsuhiko Yasuma et al. Clinical Significance of IgG Anti-Sm Antibodies in Patients with Systemic LupusErythematosus. J Rheumatol, 1990. 17:4: 469-475.11. Aeschlimann A et al. Anti-Scl-70 antibodies detected by immunoblotting in progressive systemic sclerosis:specificity and clinical correlations. Annals of Rheumatic Diseases, 1989. 48: 992-997.12. Cornin ME, Miller FW, Plotz PH. Polymyositis and Dermatomyositis. Arthritis Foundation Atlanta GA. 1988.Chapter 21: 120-123.13. Protein Reference Unit Handbook of Autoimmunity (3rd Edition) 2004 Ed A Milford Ward. J. Sheldon, GDWild. Publ. PRU Publications, Sheffield. 14.14. Tan EM et al. A critical evaluation of enzyme immunoassays for the detection of antinuclear antibodies ofdefined specificities. Arthritis and Rheum. 1999; 42 (3): 455-464.15. Biosafety in Microbiological and Biomedical Laboratories. Center for Disease Control/National Institute ofHealth, 2007, Fifth Edition.Fabricante:INOVA Diagnostics, Inc.9900 Old Grove RoadSan Diego, CA 92131United States of AmericaTechnical Service (U.S. & Canada Only) : 877-829-4745Technical Service (Outside the U.S.) :00+ 1 858-805-7950support@inovadx.comRepresentante Autorizado:Medical Technology Promedt Consulting GmbHAltenhofstrasse 80D-66386 St. Ingbert, GermanyTel.: +49-6894-581020Fax.: +49-6894-581021www.mt-procons.com624715ESP July 2012Revision 1QUANTA Lite y INOVA Diagnostics son marcas comerciales registradas de Derecho de Autor 2011 Todos los derechos reservados ©7